High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease

Harefuah

Volumn 139, Issue 5-6, 2000, Pages 174-179+247

  Avigdor, A ^a   Hardan, I ^a   Shpilberg, O ^a   Raanani, P ^a   Grotto, I ^a   Ben Bassat, I ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARMUSTINE; COMBINED MODALITY THERAPY; CYTARABINE; DACARBAZINE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; MELPHALAN; MIDDLE AGED; PODOPHYLLOTOXIN; PREDNISONE; PROCARBAZINE; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; VINBLASTINE; VINCRISTINE;

EID: 0033768070     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure
2. Hodgkin's disease: Results in patients relapsing more then 12 month after first complete remission
3. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD
4. Comparison between conventional salvage therapy and high dose therapy with autografting for recurrent or refractory Hodgkin's disease
5. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
6. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT
7. Intensive chemotherapy with cyclophosphamide, carmustime and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease
8. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long-term follow-up in 128 patients
9. The place of hige dose BEAM therapy and autologous bone marrow transplantation in poor risk Hodgkin's disease. A single center 8-year study of 155 patients
10. High-dose cyclophosphamide, carmustime and etoposide with or without cisplatin and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy
11. Comparison of high dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study
12. High dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of Stanford University results and prognostic indices
13. Non parametric estimation from incomplete observation
14. Prognostic factors for survival after high dose therapy and autologous stem cell transplantation for patients relapsing Hodgkin's disease: Analysis of 280 patients from the French registry
15. Thirty percent of adult patients with primary refractory Hodgkin's disease are progression free at 5 years after high dose therapy and autologous transplantation: Data from 290 patients reported to the EBMT
16. High-dose cyclophosphamide, carmustine and etoposide with autologous transplantation in Hodgkin's disease: A prognostic model for treatment outcomes
17. High dose chemotherapy with or without total body irradiation followed by autologous bone marrow and peripheral stem cell transplantation for Hodgkin's disease in first relapse after combination chemotherapy
18. A prognostic score for advanced Hodgkin's disease
19. What is the role for adjuvant radiation therapy in advanced Hodgkin's disease?
20. Patterns of failure following high dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease
21. High dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: The impact of involved field radiotherapy on patterns of failure and survival
22. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma
23. Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy
24. Allogeneic bone marrow transplant is not better then autologous transplant with relapsed Hodgkin's disease